Genor Biopharma Co., Ltd. clinical trials
Acquired by Edding Genor Group Holdings Limited, Dec 30, 2025 · source ↗
The registry lists 24 studies whose lead sponsor is Genor Biopharma Co., Ltd.. 4 are recruiting or about to start. Per ClinicalTrials.gov, last updated Apr 30, 2025.
Before and after it joined Edding Genor Group Holdings Limited
- First submitted before Genor Biopharma Co., Ltd. became part of Edding Genor Group Holdings Limited
- 24
- First submitted after Genor Biopharma Co., Ltd. became part of Edding Genor Group Holdings Limited
- 0
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Genor Biopharma Co., Ltd.24 studies
Something wrong with this grouping? Tell us on the Edding Genor Group Holdings Limited page.
Studies
Recruiting first, then most recently updated. Showing 24 of 24. All Edding Genor Group Holdings Limited studies →
- A Phase I, First-in-Human Study of GB268 (PD-1/CTLA-4/VEGF Trispecific Antibody) in Advanced Solid TumorsNot yet recruitingNCT06934616Phase 1
Sponsor listed in the registry: Genor Biopharma Co., Ltd. · First submitted before Genor Biopharma Co., Ltd. became part of Edding Genor Group Holdings Limited
- A Safety, Tolerability, Pharmacokinetics and Efficacy Study of GB261 in B-Cell NHL and CLL.RecruitingNCT04923048Phase 1/2
Sponsor listed in the registry: Genor Biopharma Co., Ltd. · First submitted before Genor Biopharma Co., Ltd. became part of Edding Genor Group Holdings Limited
- A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast CancerRecruitingNCT05851014Phase 3
Sponsor listed in the registry: Genor Biopharma Co., Ltd. · First submitted before Genor Biopharma Co., Ltd. became part of Edding Genor Group Holdings Limited
- A Safety, Tolerability, PK and Preliminary Activity Study of GB263T in Advanced NSCLC and Other Solid TumorRecruitingNCT05332574Phase 1/2
Sponsor listed in the registry: Genor Biopharma Co., Ltd. · First submitted before Genor Biopharma Co., Ltd. became part of Edding Genor Group Holdings Limited
- GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast CancerCompletedNCT05054751Phase 3
Sponsor listed in the registry: Genor Biopharma Co., Ltd. · First submitted before Genor Biopharma Co., Ltd. became part of Edding Genor Group Holdings Limited
- A Study of [14C]GB491 in Male Healthy SubjectsCompletedNCT05860582Phase 1
Sponsor listed in the registry: Genor Biopharma Co., Ltd. · First submitted before Genor Biopharma Co., Ltd. became part of Edding Genor Group Holdings Limited
- A Phase Ib Study of GB491 Plus Letrozole in Patients With Advanced Breast CancerStatus unknownNCT05337657Phase 1
Sponsor listed in the registry: Genor Biopharma Co., Ltd. · First submitted before Genor Biopharma Co., Ltd. became part of Edding Genor Group Holdings Limited
- Phase I Clinical Trial in Chinese Patients of Advanced and (or) Recurrent Solid Tumor/LymphomaStatus unknownNCT03374007Phase 1
Sponsor listed in the registry: Genor Biopharma Co., Ltd. · First submitted before Genor Biopharma Co., Ltd. became part of Edding Genor Group Holdings Limited
- Single Dose Pharmacokinetic Study of GB221 in Comparison With Herceptin ®CompletedNCT04905667Phase 1
Sponsor listed in the registry: Genor Biopharma Co., Ltd. · First submitted before Genor Biopharma Co., Ltd. became part of Edding Genor Group Holdings Limited
- Clinical Trial in Chinese Patients of Relapsed and Refractory Peripheral T Cell Lymphoma (GB226)Status unknownNCT03502629Phase 2
Sponsor listed in the registry: Genor Biopharma Co., Ltd. · First submitted before Genor Biopharma Co., Ltd. became part of Edding Genor Group Holdings Limited
- A Study in Recurrent or Metastatic Cervical Cancer Patients With PD-L1 PositiveStatus unknownNCT03808857Phase 2
Sponsor listed in the registry: Genor Biopharma Co., Ltd. · First submitted before Genor Biopharma Co., Ltd. became part of Edding Genor Group Holdings Limited
- Clinical Trial in Chinese Patients of B-cell Non-Hodgkin's Lymphoma(GB226)Status unknownNCT03639181Phase 2
Sponsor listed in the registry: Genor Biopharma Co., Ltd. · First submitted before Genor Biopharma Co., Ltd. became part of Edding Genor Group Holdings Limited
- Clinical Trial in Chinese Patients of Elapsed/Metastatic/Unresectable Alveolar Soft Part Sarcoma(GB226)Status unknownNCT03623581Phase 2
Sponsor listed in the registry: Genor Biopharma Co., Ltd. · First submitted before Genor Biopharma Co., Ltd. became part of Edding Genor Group Holdings Limited
- Clinical Study of Recombinant Anti-HER2 Humanized Monoclonal Antibody for InjectionStatus unknownNCT04170595Phase 1/2
Sponsor listed in the registry: Genor Biopharma Co., Ltd. · First submitted before Genor Biopharma Co., Ltd. became part of Edding Genor Group Holdings Limited
- Safety and Efficacy of Genolimzumab (GB226) in Combination With FruquintinibStatus unknownNCT03976856Phase 1
Sponsor listed in the registry: Genor Biopharma Co., Ltd. · First submitted before Genor Biopharma Co., Ltd. became part of Edding Genor Group Holdings Limited
- Geptanolimab(GB226) Combined With Fruquintinib in the Treatment of Metastatic Colorectal CancerStatus unknownNCT03977090Phase 1
Sponsor listed in the registry: Genor Biopharma Co., Ltd. · First submitted before Genor Biopharma Co., Ltd. became part of Edding Genor Group Holdings Limited
- Clinical Trial of Comparative Study of GB221 PharmacokineticsCompletedNCT04175171Phase 1
Sponsor listed in the registry: Genor Biopharma Co., Ltd. · First submitted before Genor Biopharma Co., Ltd. became part of Edding Genor Group Holdings Limited
- Phase I Clinical Study of GB222 to Evaluate the Safety, Tolerability and PK Profiles.Status unknownNCT04178057Phase 1
Sponsor listed in the registry: Genor Biopharma Co., Ltd. · First submitted before Genor Biopharma Co., Ltd. became part of Edding Genor Group Holdings Limited
- A Study to Evaluate the Safety and Tolerability of Multiple Doses of Gerilimzumab in Rheumatoid Arthritis PatientsStatus unknownNCT04179513Phase 1
Sponsor listed in the registry: Genor Biopharma Co., Ltd. · First submitted before Genor Biopharma Co., Ltd. became part of Edding Genor Group Holdings Limited
- Clinical Comparative Study to Evaluate the Efficacy and Safety of Recombinant Anti-TNF-alpha Antibodies for InjectionStatus unknownNCT04178850Phase 3
Sponsor listed in the registry: Genor Biopharma Co., Ltd. · First submitted before Genor Biopharma Co., Ltd. became part of Edding Genor Group Holdings Limited
- Phase Ⅰ Clinical Trial of Gerilimzumab Injection in Healthy SubjectsStatus unknownNCT04178070Phase 1
Sponsor listed in the registry: Genor Biopharma Co., Ltd. · First submitted before Genor Biopharma Co., Ltd. became part of Edding Genor Group Holdings Limited
- Phase Ⅰ Clinical Study Protocol of GB223 Monoclonal Antibody InjectionStatus unknownNCT04178044Phase 1
Sponsor listed in the registry: Genor Biopharma Co., Ltd. · First submitted before Genor Biopharma Co., Ltd. became part of Edding Genor Group Holdings Limited
- Clinical Trial in Chinese Healthy Volunteers of GB222Status unknownNCT04175158Phase 1
Sponsor listed in the registry: Genor Biopharma Co., Ltd. · First submitted before Genor Biopharma Co., Ltd. became part of Edding Genor Group Holdings Limited
- Clinical Study of Recombinant Anti-HER2 Humanized Monoclonal Antibody (GB221) for InjectionStatus unknownNCT04164615Phase 3
Sponsor listed in the registry: Genor Biopharma Co., Ltd. · First submitted before Genor Biopharma Co., Ltd. became part of Edding Genor Group Holdings Limited